이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

BerGenBio 관리

관리 기준 확인 2/4

BerGenBio's CEO는 Martin Olin, Sep2021 에 임명되었습니다 의 임기는 2.75 년입니다. 총 연간 보상은 NOK 10.23M, 51.5% 로 구성됩니다. 51.5% 급여 및 48.5% 보너스(회사 주식 및 옵션 포함). 는 NOK 341.55K 가치에 해당하는 회사 주식의 0.078% 직접 소유합니다. 341.55K. 경영진과 이사회의 평균 재임 기간은 각각 2.7 년과 1.9 년입니다.

주요 정보

Martin Olin

최고 경영자

NOK 10.2m

총 보상

CEO 급여 비율	51.5%
CEO 임기	2.8yrs
CEO 소유권	0.08%
경영진 평균 재임 기간	2.7yrs
이사회 평균 재임 기간	1.9yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Martin Olin 의 보수는 BerGenBio 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-NOK 155m
Dec 31 2023	NOK 10m	NOK 5m	-NOK 190m
Sep 30 2023	n/a	n/a	-NOK 226m
Jun 30 2023	n/a	n/a	-NOK 258m
Mar 31 2023	n/a	n/a	-NOK 293m
Dec 31 2022	NOK 11m	NOK 5m	-NOK 302m
Sep 30 2022	n/a	n/a	-NOK 294m
Jun 30 2022	n/a	n/a	-NOK 304m
Mar 31 2022	n/a	n/a	-NOK 309m
Dec 31 2021	NOK 4m	NOK 1m	-NOK 309m

보상 대 시장: Martin 의 총 보상 ($USD 970.93K )은 UK 시장( $USD 358.65K ).

보상과 수익: Martin 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Martin Olin (55 yo)

2.8yrs

테뉴어

NOK 10,231,670

보상

Mr. Martin Olin serves as Chief Executive Officer at BerGenBio ASA since September 8, 2021. Mr. Olin has been Chairman of the Board at AcouSort AB (publ) since April 28, 2021. He has experience from execut...

리더십 팀

이름	위치	테뉴어	보상	소유권
Martin Olin	Chief Executive Officer	2.8yrs	NOK 10.23m	0.078% NOK 361.4k
Rune Skeie	Chief Financial Officer	6.3yrs	NOK 3.59m	0.010% NOK 46.3k
Cristina Oliva	Chief Medical Officer	2.2yrs	NOK 5.70m	데이터 없음
Graham Morell	Head of IR	no data	데이터 없음	데이터 없음
Gayle Mills	Chief Business Officer	2.6yrs	NOK 3.39m	데이터 없음
Akil Jackson	Medical Director	no data	데이터 없음	데이터 없음

2.7yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: 0RU5 의 관리팀은 경험 ( 2.7 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Sally Bennett	Independent Non-Executive Director	3.5yrs	NOK 358.00k	0.012% NOK 56.2k
Sveinung Hole	Independent Non-Executive Director	13.8yrs	NOK 335.00k	0.077% NOK 357.0k
John Heymach	Member of Scientific Advisory Board	1.3yrs	데이터 없음	데이터 없음
Shu Kam Mok	Member of Scientific Advisory Board	1.3yrs	데이터 없음	데이터 없음
Enriqueta Felip	Member of Scientific Advisory Board	1.3yrs	데이터 없음	데이터 없음
Debra Barker	Independent Non-Executive Director	5.3yrs	NOK 344.00k	0.012% NOK 55.5k
Anders Tullgren	Independent Chairman of the Board	2.4yrs	NOK 848.00k	0.055% NOK 257.6k
Solange Peters	Member Scientific Advisory Board	1.3yrs	데이터 없음	데이터 없음

1.9yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: 0RU5 의 이사회는 경험(평균 재직 기간 1.9 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

BerGenBio 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

BerGenBio ASA Announces Resignation of Francois Thomas from the Board of Directors

High number of new and inexperienced directors

Recent updates

High number of new and inexperienced directors

New major risk - Market cap size

High number of new and inexperienced directors

High number of new and inexperienced directors

New major risk - Financial position

BerGenBio ASA Announces Closure of EU-Solidact Bemcentinib Study Arm in Hospitalized COVID-19 Patients

BerGenBio ASA Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at the 2023 ASH Meeting

BerGenBio ASA has completed a Follow-on Equity Offering in the amount of €240.87 million.

New major risk - Financial position

BerGenBio ASA to Report Q4, 2024 Results on Feb 19, 2025

BerGenBio ASA Announces Full Results of its Phase 2 BGBC008 Study of Bemcentinib and Pembrolizumab in Second Line Non-Small Cell Lung Cancer

New major risk - Shareholder dilution

BerGenBio ASA has completed a Follow-on Equity Offering in the amount of NOK 250 million.

High number of new and inexperienced directors

BerGenBio Announces Data from Bemcentinib Trial in Mesothelioma Presented at ASCO

BerGenBio ASA Announces Resignation of Francois Thomas from the Board of Directors

BerGenBio ASA to Report Q1, 2023 Results on Jun 22, 2023

High number of new and inexperienced directors

High number of new and inexperienced directors

BerGenBio ASA Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients

BerGenBio ASA Announces Board Appointments

BerGenBio ASA to Report Q3, 2023 Results on Nov 14, 2023

BerGenBio ASA Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations

BerGenBio ASA Announces First Patient Randomized in Bemcentinib Trial in Eu-Solidact Platform for Hospitalized Covid-19 Patients

BerGenBio ASA Provides Update on Clinical Development

Chairman of the Board recently bought kr268k worth of stock

BerGenBio ASA Announces Complete Data Analysis of Accord2 Phase II Bemcentinib Study in Hospitalized Covid-19 Patients - Primary Efficacy Endpoint Met

Bergenbio Presents Bemcentinib Covid-19 Clinical Trial Data At Eccmid 2022

BerGenBio ASA Appoints Cristina Oliva as Chief Medical Officer, Effective April 25, 2022

High number of new and inexperienced directors

Chief Executive Officer recently bought kr204k worth of stock

BerGenBio ASA Completes Recruitment of Phase II AML Study ((BGBC003)

Chief Executive Officer Richard Godfrey has left the company

BerGenBio ASA Presents Encouraging Combined Data for Bemcentinib from Two Phase II Covid-19 Studies At Eccmid

BerGenBio ASA Updates Preliminary Survival Data from the Ongoing Phase II Study of Bemcentinib

BerGenBio ASA Receives Food and Drug Administration Fast Track Designation for Bemcentinib / Anti-Pd-(L)1 Combination in NSCLC

BerGenBio ASAPresents Data from Phase I/II Bemcentinib/Erlotinib Combination Trial in NSCLC

BerGenBio ASA to Present Data from Phase I/II Bemcentinib/Erlotinib Combination Trial in NSCLC at ASCO Meeting

BerGenBio ASA Announces Top Line Data from Phase II Trial Assessing Bemcentinib in Hospitalised Covid-19 Patients

BerGenBio ASA Announces Pre-Clinical COVID-19 Data Presented at Virtual Immunology 2021

BerGenBio ASA Completes Enrolment into Latest Cohort of Phase II Bemcentinib Combination Study in Refractory NSCLC

BerGenBio ASA Announces Start of Phase 1B Trial of Anti-AXL Antibody Tilvestamab (BGB149)

BerGenBio ASA Closes Recruitment into Trial Assessing Bemcentinib in Covid-19 Patients

BerGenBio ASA Announces Second Data Monitoring Committee Recommends Continuation of Bergenbio's BGBC020 Trial Assessing Bemcentinib in COVID-19 Patients

BerGenBio ASA Presents an Update from Its Phase II Study of Bemcentinib in Combination with Anti-PD-1 Therapy Pembrolizumab (Bgbc008)

Bergenbio to Present Updates from Ongoing Phase II Bemcentinib Combination Study in Refractory NSCLC At WCLC 2020

BerGenBio ASA to Report Q4, 2020 Results on Feb 10, 2021

BerGenBio ASA to Report Q3, 2021 Results on Nov 16, 2021

BerGenBio ASA Presents Updated Clinical Data from Two Phase II Studies of Bemcentinib in AML and MDS Patients at ASH 2020

BerGenBio ASA Confirms First Patient Enrolled in Phase II Trial Assessing Bemcentinib as Potential Treatment for COVID-19 in India

Revenue in line with expectations

BerGenBio ASA Presents Phase II Bemcentinib Combination Study in NSCLC At Annual SITC Meeting

BerGenBio ASA to Present Clinical Translational Data from the Ongoing Phase II Bemcentinib Combination Study in NSCLC At Annual SITC Meeting

BerGenBio Presents Data on Anti-Axl Antibody Tilvestamab

BerGenBio Announces First Patient Dosed with Bemcentinib in Relapsed Malignant Pleural Mesothelioma Investigator Sponsored Phase IIa Study

Bergenbio ASA Receives Regulatory Approval from the India Regulatory Authority to Proceed with Phase II Clinical Trial to Assess the Efficacy and Safety of Bemcentinib

BerGenBio ASA Receives Approval from Norwegian Regional Ethics Committee for COVID-19 South Africa Trial

BerGenBio ASA to Report Q2, 2020 Results on Aug 18, 2020

First half earnings released

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령